Rates of grade 3/4 TEAEs were 11.89 per 100 patient-months among MRD-negative patients and 17.65 per 100 patient-months among MRD-positive patients in PERSEUS, and 11.34 and 13.15 per 100 ...

The CEPHEUS trial is a trial for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplantation, or in whom a transplant was deferred. And 395 patients were randomized ...

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and ...

The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.

Of these progression-free patients, 12 from a single center with serial MRD assessments were all MRD-negative and imaging-negative at year 5 or later after cilta-cel without additional therapy, ...

CHICAGO -- Patients with undetectable disease after induction therapy for newly diagnosed multiple myeloma (NDMM) did not have significantly better outcomes with a stem-cell transplant versus drug ...

Researchers found that the outcomes were excellent for the 178 end of first consolidation measurable residual disease (MRD)-negative patients, regardless of MRD results at later time points. HealthDay ...

A Darzalex-based regimen improved MRD negativity rates compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma. Darzalex (daratumumab) plus Velcade (bortezomib), ...

(RTTNews) - Johnson & Johnson (JNJ) announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) significantly increased ...